Prospekta
Phase 3Small molecule
Prospekta is one of 30 small molecule programs targeting Psychiatric Disorder. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
28 competitors in Psychiatric Disorder
#DrugCompanyPhaseTrials
1Wellbutrin
GSKApproved
Chantix
PfizerApproved
Nicorette
PfizerApproved
Lexapro
AbbVieApproved
Chantix
PPrism Pharmaceuticals
Approved
Nicotine Free Cigarettes
PfizerApproved
Pitocin
RRetrophin
Approved
Suboxone
IIndivior Inc.
Approved
Brintellix
TakedaPhase 3
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Asthenia1 trial
Psychiatric Disorder1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Prospekta. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMateria Medica Holding